APN 411
Alternative Names: APN-411Latest Information Update: 28 Oct 2022
Price :
$50 *
At a glance
- Originator Apeiron Biologics
- Class Antineoplastics; Small molecules
- Mechanism of Action Ubiquitin protein ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
- Discontinued Autoimmune disorders
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Cancer in Austria (Parenteral)
- 20 Jan 2022 Discontinued - Preclinical for Autoimmune disorders in Austria (Parenteral) (Evotec pipeline, January 2022)
- 27 Oct 2020 APN 411 is still in preclinical trials for Cancer in Austria (Evotec pipeline, October 2020)